Sustained HIV Viral Suppression 18 Months After the Last Dose of Long-acting Cabotegravir/Rilpivirine: A Case Report

2025/06/30 by Shawnalyn W Sunagawa, Sara H Bares, Kimberly K. Scarsi +8 · 1 voice
Medicine · Immunology and Microbiology · #HIV/AIDS drug development and treatment #HIV Research and Treatment #Hepatitis C virus research

paper · pdf · doi:10.1093/ofid/ofaf399

Abstract

Long-acting cabotegravir/rilpivirine offers a low incidence of virologic failure. However, drug resistance can develop after discontinuation without an effective replacement regimen due to its long pharmacokinetic tail. We present a case of sustained virologic suppression 18 months after discontinuation of long-acting cabotegravir/rilpivirine despite inadequate adherence to oral antiretroviral therapy.

Citations

• Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis

Discussions

• Sustained HIV Viral Suppression 18 Months Post-Last Dose of Long-Acting Cabotegravir/Rilpivirine: A Case Report ✅ Just Accepted #IDSky [bsky, 8 points, 0 comments]

Related

• Virological History Predicts Non-sustained Viral Suppression With Long-Acting Cabotegravir and Rilpivirine Therapy, Independent of Pharmacokinetic Parameters
• Assessment of Failures of Long-acting Cabotegravir and Rilpivirine in a Real-world Treatment Setting
• Virologic Failure and Emergent Integrase Strand Transfer Inhibitor Drug Resistance With Long-Acting Cabotegravir for HIV Treatment: A Meta-analysis
• Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis
• Clinical Consequences of Delaying Implementation of Long-Acting Antiretroviral Therapy for People With HIV and Persistent Viremia in the United States